Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on October 16, 2006.
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- University of Lahore
- Target Recruit Count
- 50
- Registration Number
- NCT06952231
- Locations
- 🇵🇰
The University of Lahore, Lahore, Punjab, Pakistan
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes Clinical Trial
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
- Target Recruit Count
- 504
- Registration Number
- NCT06851962
- Locations
- 🇪🇸
Hospital Universitario Regional de Málaga, Málaga, Spain
🇪🇸Hospital Clínico Universitario de Valencia, Valencia, Spain
🇪🇸Hospital General Universitario de Valencia (HGUV), Valencia, Spain
DPP4-Inhibitors and Bone Metabolism in Diabetes
- Conditions
- OsteoporosisBone Loss, PostmenopausalDiabetes Mellitus Type 2
- Interventions
- Drug: Placebo Tablets
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Azienda Policlinico Umberto I
- Target Recruit Count
- 132
- Registration Number
- NCT06770894
- Locations
- 🇮🇹
AOU Policlinico Umberto I, University La Sapienza, Rome, Italy
Emulation of the SOUL Diabetes Trial in Healthcare Claims
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 43650
- Registration Number
- NCT06659718
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity
- Conditions
- Type 2 Diabetes MellitusGlucotoxicity
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-09-26
- Lead Sponsor
- Zhibin Xu
- Target Recruit Count
- 129
- Registration Number
- NCT06613750
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS
- Conditions
- Polycystic Ovarian Syndrome
- Interventions
- First Posted Date
- 2024-09-09
- Last Posted Date
- 2024-09-09
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06587698
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Eurofarma Laboratorios S.A.
- Target Recruit Count
- 612
- Registration Number
- NCT06560333
- Locations
- 🇧🇷
Eurofarma Laboratorios S.A, São Paulo, SP, Brazil
Doxycycline in Type II Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Mostafa Bahaa
- Target Recruit Count
- 60
- Registration Number
- NCT06329882
- Locations
- 🇪🇬
Tanta Unuversity, Tanta, Egypt
Anti-Diabetic Medications to Fight PD and LBD
- Conditions
- Lewy Body DementiaParkinson Disease
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT06263673
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
- Conditions
- Type 2 Diabetes (Adult Onset)
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-02-24
- Target Recruit Count
- 256
- Registration Number
- NCT06246799
- Locations
- 🇺🇸
University Health System Texas Diabetic Institute, San Antonio, Texas, United States
🇺🇸UT Health Science Center, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.